The compounded semaglutide window closes at 11:59 p.m. on Tuesday, April 22. [1] After that, state-licensed 503A pharmacies — the bulk of the compounding ecosystem — lose the enforcement discretion that has kept Ozempic's active ingredient flowing at a fraction of Novo Nordisk's list price since the drug first landed on the FDA shortage list in 2022.

The FDA removed semaglutide from the shortage list earlier this year, which is the legal event that triggers Tuesday's cutoff. [2] Novo launched its once-daily oral Wegovy tablet in January, which the agency treated as sufficient evidence that access was no longer constrained. [3] The companies that had built whole clinical workflows around $150-a-month compounded pens — Hims & Hers, Ro, Henry Meds, Weight Watchers' telehealth arm, hundreds of medical spas — have been warning patients since February. Most patients have not yet chosen a replacement.

The service-journalism answer is narrow: if you are on compounded semaglutide and you have not already had the conversation, have it Monday. Three paths are open. Brand-name Ozempic or Wegovy at list price or through a payer's weight-loss benefit if one exists. The daily oral Wegovy tablet, which requires 30-minute pre-dose fasting and costs roughly what compounded injectable cost on the cash market. [4] Or tirzepatide, Eli Lilly's dual-agonist, which remains compoundable in some jurisdictions under separate FDA enforcement posture and which many patients tolerate as well or better.

The clinical consideration that matters most on Monday is the dose cliff. Compounded semaglutide is typically titrated in 0.25-mg weekly increments; brand-name comes in fixed-dose pens (0.25, 0.5, 1.0, 1.7, 2.4 mg). A patient mid-titration on 0.6 mg of compounded product has to decide whether to round down to 0.5 or up to 1.0 — and the answer depends on GI tolerance, not arithmetic. A prescriber consultation before the last refill is the only way to avoid either a two-week gap or a nausea setback.

Insurance is the second cliff. Commercial plans that excluded weight-loss indications in 2024 have begun adding coverage for obesity under CMS pressure, but coverage is not uniform, and prior authorizations routinely take 10 to 14 days. [5] A patient who calls the payer Monday morning and starts the PA Monday afternoon will likely be out of product for one or two doses. Patients on Medicaid or Medicare should ask specifically about cardiovascular or diabetes indications, which have broader coverage than obesity alone.

The third question is whether to switch molecule. Tirzepatide (Mounjaro, Zepbound) has shown greater weight loss in head-to-head trials and remains available compounded in several states, though the FDA has signaled that its separate compounding framework is also under review. [6] Patients who have tolerated semaglutide well may prefer to stay on brand; those who have plateaued may use Tuesday's forcing function to switch.

What will not work is waiting. The Lilly v. Empower Pharmacy ruling in February narrowed the compounded-GLP-1 defense; state boards have begun issuing cease-and-desist letters to 503A operations that have publicly committed to continuing semaglutide compounding past Tuesday. [7] The drug will be available. The $150 version, from a compounding pharmacy shipped to a home address with minimal clinician oversight, largely will not be.

Four days is enough to book a telehealth appointment, start a prior authorization, and pick up a branded pen on Tuesday night. It is not enough to do any of those things sequentially. Do them in parallel. The hundreds of thousands of Americans who have lost 15 or 20 or 40 pounds on compounded semaglutide should not have to relearn that weight loss next month.

-- NORA WHITFIELD, Chicago